AGIO Stock Analysis: Mitapivat FDA Priority Review, November 2026 PDUFA Date and the Sickle Cell Disease Opportunity
AGIO Stock Analysis: Mitapivat FDA Priority Review, November 2026 PDUFA Date and the Sickle Cell Disease Opportunity Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) surged after the U.S. Food and Drug Administration granted Priority Review to the company’s supplemental New Drug Application for mitapivat in sickle cell disease. The FDA assigned a PDUFA goal date of November … Read more